Scilex Holding (SCLXW) Depreciation & Amortization (CF) (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Depreciation & Amortization (CF) of $2.9 million in Q1 2026, up 80.78% quarter-over-quarter from $1.6 million in Q4 2025, and up 186.04% on a YoY basis from $1.0 million in Q1 2025.
Scilex Holding (SCLXW) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Scilex Holding's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 186.04% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $6.5 million (up 61.5% YoY), while the FY2025 annual figure was $4.6 million, up 14.26% from the prior year.
- Depreciation & Amortization (CF) was $2.9 million for Q1 2026 at Scilex Holding, up from $1.6 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.9 million in Q1 2026 to a low of $944000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $1.2 million across 5 years, with a median of $1.0 million in 2024.
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) fell 3.27% in 2024, then soared 186.04% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.0 million in 2022, then decreased by 0.1% to $1.0 million in 2023, then slipped by 2.9% to $1.0 million in 2024, then surged by 58.07% to $1.6 million in 2025, then surged by 80.78% to $2.9 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.9 million (Q1 2026), $1.6 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 509.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 594.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |